Abstract: Methods for intravenous dosing of antibodies to human neonatal Fc receptor (FcRn) are described. The anti-FcRn antibodies are useful, e.g., to promote clearance of autoantibodies in a subject, to suppress antigen presentation in a subject, to block an immune response, e.g., block an immune complex-based activation of the immune response in a subject, or to treat immunological diseases (e.g., autoimmune diseases) in a subject.

Abstract: Methods for dosing of antibodies to human neonatal Fc receptor (FcRn) are described. The anti-FcRn antibodies are useful, e.g., to promote clearance of autoantibodies in a subject, to suppress antigen presentation in a subject, to block an immune response, e.g., block an immune complex-based activation of the immune response in a subject, or to treat immunological diseases (e.g., autoimmune diseases) in a subject.

Abstract: Compositions comprising a highly sialylated IgG preparation and methods for treating a patient using such preparations are described. This application is based, in part, on the surprising discovery that a dose of a highly sialylated IgG (hsIgG) preparation that is about 1%-10% of the effective dose for IVIG can be effective for treating disorders that are treated with IVIG.

Abstract: Automatically controlled adjustable dump orifices (ADO) for use with liquid jet cutting systems are disclosed herein. In some embodiments, the automatically controlled ADOs described herein include a motor (e.g., an electric motor) and a coupling configured to operably couple the motor to a valve. The valve is configured to cooperate with a dump orifice connected in fluid communication with a high-pressure pump of the cutting system. The motor is operable to move the valve in a first direction to increase the pressure of high-pressure liquid (e.g., water) flowing through the dump orifice and in a second direction, opposite to the first direction, to reduce the pressure of the high-pressure liquid flowing through the dump orifice.

Abstract: This invention is directed to methods of inhibiting coagulation or treating thrombosis using a factor Xa inhibitor and a P-glycoprotein (Pgp) inhibitor. The invention is also directed to formulations used in the methods.

Abstract: This invention is directed to methods of inhibiting coagulation or treating thrombosis using a factor Xa inhibitor and a P-glycoprotein (Pgp) inhibitor. The invention is also directed to formulations used in the methods.

Abstract: An electronic control logic system for processing the results of a spectrophotometer analysis of a serum chemistry comprised of a serum and one or more chemical reagents. The spectrophotometer output representing air as a light path and another output representing the test chemistry as a light path are integrated and the air path integrated value allowed to exponentially decay until its value is equal to that of the integrated test chemistry path value. The decay time is converted into a train of digital pulses representative of the optical density of the test chemistry. These pulses are counted and their total stored for comparison with the corresponding optical density of a standard solution. The concentration of the element for which the particular test was designed to detect is known for the standard solution, so the percentage concentration of that element in the test chemistry may be thereby ascertained.